---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045283"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:20:55.344104+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M

## Summary
- GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.
- VEVYE prescriptions up 55% QoQ; IHEEZO unit demand up 15% QoQ; TRIESENCE relaunched in October.
- Cash $72.6M; $37M milestone payment for TRIESENCE funded by $30M Oaktree drawdown.
- First major Medicare Part D win for VEVYE with Express Scripts, Cigna, Kaiser, CVS Caremark.
- FY2024 revenue guidance reaffirmed at >$180M; Q4 expected to significantly outpace Q3.

## SEC filing metadata
- accession: 0001493152-24-045283
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/0001493152-24-045283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045283
- JSON: https://secwatch.observer/filing/0001493152-24-045283.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.